| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Babak Baban | |
| Lei Huang | |||
| Andrew L Mellor | |||
| Burles A Johnson | |||
| P2860 | cites work | Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer | Q56786153 |
| The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells | Q56902123 | ||
| Activation requirements for the induction of CD4+CD25+ T cell suppressor function | Q56903555 | ||
| When ligand becomes receptor--tolerance via B7 signaling on DCs | Q56904184 | ||
| Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy | Q58855390 | ||
| Mucosal CD8alpha+ DC, with a plasmacytoid phenotype, induce differentiation and support function of T cells with regulatory properties | Q73196801 | ||
| Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation | Q73567305 | ||
| Dendritic cells have the option to express IDO-mediated suppression or not | Q81474897 | ||
| Tuberculosis is associated with a down-modulatory lung immune response that impairs Th1-type immunity | Q84080100 | ||
| Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase–dependent DC functions and regulates experimental graft-versus-host disease in mice | Q24288997 | ||
| Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice | Q24305475 | ||
| Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan | Q24328949 | ||
| Prevention of allogeneic fetal rejection by tryptophan catabolism | Q24336018 | ||
| Essential role for CD103 in the T cell-mediated regulation of experimental colitis | Q24646106 | ||
| Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase | Q28115622 | ||
| Inhibition of T cell proliferation by macrophage tryptophan catabolism | Q28142922 | ||
| Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase | Q28204166 | ||
| Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific | Q28254589 | ||
| Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses | Q28283999 | ||
| Induction of IDO by bacille Calmette-Guérin is responsible for development of murine depressive-like behavior | Q28508390 | ||
| Indoleamine 2,3-dioxygenase in lung dendritic cells promotes Th2 responses and allergic inflammation | Q28591402 | ||
| Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity. | Q30374900 | ||
| Small intestinal CD103+ dendritic cells display unique functional properties that are conserved between mice and humans. | Q33361113 | ||
| Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer | Q33482453 | ||
| Anti-CTLA-4 treatment induces IL-10-producing ICOS+ regulatory T cells displaying IDO-dependent anti-inflammatory properties in a mouse model of colitis | Q34048386 | ||
| Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. | Q34394487 | ||
| Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. | Q34655953 | ||
| The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation | Q34657284 | ||
| Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. | Q34657500 | ||
| A sense of tumour for the immune system | Q34842108 | ||
| Indoleamine 2,3-dioxygenase-expressing dendritic cells form suppurative granulomas following Listeria monocytogenes infection | Q35131219 | ||
| HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells | Q35751070 | ||
| Inhibition of experimental asthma by indoleamine 2,3-dioxygenase | Q35835456 | ||
| Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. | Q35835489 | ||
| Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase | Q35925641 | ||
| 3-Hydroxyanthranilic acid inhibits PDK1 activation and suppresses experimental asthma by inducing T cell apoptosis | Q36276917 | ||
| CTLA-4-Ig activates forkhead transcription factors and protects dendritic cells from oxidative stress in nonobese diabetic mice | Q36399304 | ||
| Dendritic cells in a mature age. | Q36475977 | ||
| A historical perspective on immunological privilege | Q36593722 | ||
| The importance of regional lymph nodes for mucosal tolerance | Q36593742 | ||
| Expression of indoleamine 2,3-dioxygenase (IDO) by endothelial cells: implications for the control of alloresponses | Q44134414 | ||
| Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase | Q44135171 | ||
| T cell apoptosis by tryptophan catabolism | Q44137068 | ||
| CTLA-4-Ig regulates tryptophan catabolism in vivo. | Q44170968 | ||
| Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. | Q44539418 | ||
| CDllc+ cells modulate pulmonary immune responses by production of indoleamine 2,3-dioxygenase | Q44575994 | ||
| Modulation of tryptophan catabolism by regulatory T cells. | Q44632333 | ||
| Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. | Q44807466 | ||
| Human epidermal langerhans cells express the immunoregulatory enzyme indoleamine 2,3-dioxygenase | Q44971540 | ||
| Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase | Q45047397 | ||
| Induction of immunosuppressive molecules and regulatory T cells counteracts the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer | Q45871945 | ||
| Interferon-gamma-triggered indoleamine 2,3-dioxygenase competence in human monocyte-derived dendritic cells induces regulatory activity in allogeneic T cells. | Q45922663 | ||
| Reduced cytotoxic function of effector CD8+ T cells is responsible for indoleamine 2,3-dioxygenase-dependent immune suppression. | Q45947449 | ||
| Tryptophan deprivation induces inhibitory receptors ILT3 and ILT4 on dendritic cells favoring the induction of human CD4+CD25+ Foxp3+ T regulatory cells. | Q45964911 | ||
| Indoleamine 2,3 dioxygenase-mediated tryptophan catabolism regulates accumulation of Th1/Th17 cells in the joint in collagen-induced arthritis. | Q46030942 | ||
| GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. | Q46490849 | ||
| Cutting edge: silencing suppressor of cytokine signaling 3 expression in dendritic cells turns CD28-Ig from immune adjuvant to suppressant. | Q46499878 | ||
| Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation | Q46531302 | ||
| A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation | Q46557704 | ||
| Cytochrome b5, not superoxide anion radical, is a major reductant of indoleamine 2,3-dioxygenase in human cells | Q46734158 | ||
| Enhanced tryptophan catabolism in the absence of the molecular adapter DAP12. | Q46737044 | ||
| Novel action of indoleamine 2,3-dioxygenase attenuating acute lung allograft injury | Q46809300 | ||
| Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease. | Q46815296 | ||
| IDO expands human CD4+CD25high regulatory T cells by promoting maturation of LPS-treated dendritic cells | Q46941757 | ||
| CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition | Q46979779 | ||
| The countervailing actions of myeloid and plasmacytoid dendritic cells control autoimmune diabetes in the nonobese diabetic mouse. | Q53524050 | ||
| Tryptophan catabolism in IDO+ plasmacytoid dendritic cells. | Q36789443 | ||
| Indoleamine 2,3-dioxygenase and tumor-induced tolerance | Q36809762 | ||
| IDO expression in the brain: a double-edged sword | Q36861514 | ||
| IDO activates regulatory T cells and blocks their conversion into Th17-like T cells | Q36914732 | ||
| Creating immune privilege: active local suppression that benefits friends, but protects foes. | Q37026641 | ||
| SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis | Q37081582 | ||
| The importance of NAD in multiple sclerosis | Q37118012 | ||
| Th17 cell differentiation: the long and winding road | Q37133442 | ||
| Tolerization with Hsp65 induces protection against adjuvant-induced arthritis by modulating the antigen-directed interferon-gamma, interleukin-17, and antibody responses | Q37157936 | ||
| Stem cells ameliorate EAE via an indoleamine 2,3-dioxygenase (IDO) mechanism | Q37189921 | ||
| Clinical relevance of indoleamine 2,3-dioxygenase for alloimmunity and transplantation | Q37228240 | ||
| Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. | Q37234611 | ||
| Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. | Q37268984 | ||
| T cell regulatory plasmacytoid dendritic cells expressing indoleamine 2,3 dioxygenase | Q37334065 | ||
| The immunoregulatory enzyme IDO paradoxically drives B cell-mediated autoimmunity | Q37340475 | ||
| Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption. | Q37347671 | ||
| Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism | Q37349845 | ||
| Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapy | Q37352554 | ||
| Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? | Q37492248 | ||
| Targeting indoleamine 2,3-dioxygenase (IDO) to counteract tumour-induced immune dysfunction: from biochemistry to clinical development. | Q37516009 | ||
| Type II collagen oral tolerance; mechanism and role in collagen-induced arthritis and rheumatoid arthritis | Q37583662 | ||
| Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling | Q38319700 | ||
| Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. | Q38450454 | ||
| Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of ovarian carcinoma | Q39814919 | ||
| Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer | Q39843619 | ||
| Expression and prognosis role of indoleamine 2,3-dioxygenase in hepatocellular carcinoma | Q39988114 | ||
| IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism | Q39991104 | ||
| Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma | Q40041177 | ||
| Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells | Q40082326 | ||
| Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells | Q40197317 | ||
| Cutting edge: human eosinophils regulate T cell subset selection through indoleamine 2,3-dioxygenase | Q40495420 | ||
| Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division | Q40686234 | ||
| Ligand and cytokine dependence of the immunosuppressive pathway of tryptophan catabolism in plasmacytoid dendritic cells. | Q42484177 | ||
| Cell-autonomous control of interferon type I expression by indoleamine 2,3-dioxygenase in regulatory CD19+ dendritic cells. | Q42509333 | ||
| CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-gamma, and indoleamine 2,3-dioxygenase | Q42876261 | ||
| Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. | Q43514619 | ||
| IL-6 inhibits the tolerogenic function of CD8 alpha+ dendritic cells expressing indoleamine 2,3-dioxygenase | Q43664739 | ||
| Cutting edge: Autocrine TGF-beta sustains default tolerogenesis by IDO-competent dendritic cells. | Q43769122 | ||
| Effect of indoleamine 2,3-dioxygenase on induction of experimental autoimmune encephalomyelitis | Q44088414 | ||
| P433 | issue | 2 | |
| P921 | main subject | dendritic cell | Q506253 |
| P304 | page(s) | 133-155 | |
| P577 | publication date | 2010-04-01 | |
| P1433 | published in | International Reviews of Immunology | Q6052764 |
| P1476 | title | Dendritic cells, indoleamine 2,3 dioxygenase and acquired immune privilege | |
| P478 | volume | 29 |
| Q55071408 | Alterations in serum kynurenine pathway metabolites in individuals with high neocortical amyloid-β load: A pilot study. |
| Q26860162 | Anti-inflammatory therapy in chronic disease: challenges and opportunities |
| Q45813783 | Benznidazole treatment reduces the induction of indoleamine 2,3-dioxygenase (IDO) enzymatic activity in Chagas disease symptomatic patients |
| Q42490694 | CXCR3 ligands promote expression of functional indoleamine 2,3-dioxygenase in basal cell carcinoma keratinocytes. |
| Q97067698 | Co-treatments to Boost IDO Activity and Inhibit Production of Downstream Catabolites Induce Durable Suppression of Experimental Autoimmune Encephalomyelitis |
| Q34110557 | Common gamma chain cytokines promote rapid in vitro expansion of allo-specific human CD8+ suppressor T cells |
| Q27022855 | Cytosolic DNA sensing via the stimulator of interferon genes adaptor: Yin and Yang of immune responses to DNA |
| Q53170606 | Dynamic changes of indoleamine 2,3-dioxygenase of Kupffer cells in rat liver transplant rejection and tolerance. |
| Q39727068 | Elevated interleukin-27 levels in human neonatal macrophages regulate indoleamine dioxygenase in a STAT-1 and STAT-3-dependent manner |
| Q44306229 | Endoplasmic reticulum stress response and inflammatory cytokines in type 2 diabetic nephropathy: role of indoleamine 2,3-dioxygenase and programmed death-1. |
| Q35949475 | Engineering DNA nanoparticles as immunomodulatory reagents that activate regulatory T cells |
| Q37711667 | Expression and Prognostic Value of Indoleamine 2,3-dioxygenase in Pancreatic Cancer |
| Q34323684 | Forced IDO1 expression in dendritic cells restores immunoregulatory signalling in autoimmune diabetes |
| Q41780299 | Good news-bad news: the Yin and Yang of immune privilege in the eye. |
| Q34253805 | Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase |
| Q33841965 | High-throughput sequencing reveals key genes and immune homeostatic pathways activated in myeloid dendritic cells by Porphyromonas gingivalis 381 and its fimbrial mutants |
| Q50630386 | Human Chorionic Villous Mesenchymal Stem Cells Modify the Functions of Human Dendritic Cells, and Induce an Anti-Inflammatory Phenotype in CD1+ Dendritic Cells. |
| Q83014682 | Human endometrial-derived mesenchymal stem cells suppress inflammation in the central nervous system of EAE mice |
| Q34396547 | IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation |
| Q35986384 | Immunological and nonimmunological effects of indoleamine 2,3-dioxygenase on breast tumor growth and spontaneous metastasis formation |
| Q42000663 | Immunoregulatory effects of bone marrow-derived mesenchymal stem cells in the nasal polyp microenvironment. |
| Q47157913 | Indoleamine 2,3-Dioxygenase and Tolerance: Where Are We Now? |
| Q37188781 | Indoleamine 2,3-dioxygenase activity contributes to local immune suppression in the skin expressing human papillomavirus oncoprotein e7. |
| Q28588016 | Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells |
| Q38032201 | Indoleamine 2,3-dioxygenase: from catalyst to signaling function |
| Q34778943 | Induction and role of indoleamine 2,3 dioxygenase in mouse models of influenza a virus infection |
| Q37089253 | Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications |
| Q39034662 | Is Immune Modulation the Mechanism Underlying the Beneficial Effects of Amniotic Cells and Their Derivatives in Regenerative Medicine? |
| Q27003296 | Kynurenines in the mammalian brain: when physiology meets pathology |
| Q40495763 | Local gene therapy with indoleamine 2,3-dioxygenase protects against development of transplant vasculopathy in chronic kidney transplant dysfunction |
| Q35107011 | MHC molecules in health and disease: At the cusp of a paradigm shift |
| Q38067209 | Mechanisms of T cell tolerance towards the allogeneic fetus |
| Q35624272 | Meeting report of the first conference of the International Placenta Stem Cell Society (IPLASS). |
| Q38044664 | Metabolic checkpoints in activated T cells |
| Q26864319 | Metabolic reprogramming and metabolic dependency in T cells |
| Q89772300 | Mothers' distress exposure and children's withdrawn behavior - A moderating role for the Interferon Gamma gene (IFNG) |
| Q37820820 | Multifunctional dendritic cell-targeting polymeric microparticles: engineering new vaccines for type 1 diabetes |
| Q41889772 | Pancreatic islet transplants and IDO: when starving the enemy does you good |
| Q38020356 | Placental expression of indoleamine 2,3-dioxygenase |
| Q27694728 | Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior |
| Q35992355 | Recent developments on immunotherapy for brain cancer |
| Q26996330 | Role of innate immunity against human papillomavirus (HPV) infections and effect of adjuvants in promoting specific immune response |
| Q38293111 | STING, nanoparticles, autoimmune disease and cancer: a novel paradigm for immunotherapy? |
| Q48083842 | Serum Levels of High-sensitivity C-Reactive Protein at Admission Are More Strongly Associated with Poststroke Depression in Acute Ischemic Stroke than Homocysteine Levels |
| Q38725391 | Signal Transducer and Activator of Transcription 1 Plays a Pivotal Role in RET/PTC3 Oncogene-induced Expression of Indoleamine 2,3-Dioxygenase 1. |
| Q26775471 | Targeting the indoleamine 2,3-dioxygenase pathway in cancer |
| Q47714445 | The cryo-thermal therapy-induced IL-6-rich acute pro-inflammatory response promoted DCs phenotypic maturation as the prerequisite to CD4+ T cell differentiation |
| Q41898658 | The immune diet: meeting the metabolic demands of lymphocyte activation |
| Q35579203 | The immunobiology of the mammalian epididymis: the black box is now open! |
| Q42339159 | The modulation of enzyme indoleamine 2,3-dioxygenase from dendritic cells for the treatment of type 1 diabetes mellitus |
| Q34438046 | The p50 subunit of NF-κB orchestrates dendritic cell lifespan and activation of adaptive immunity |
| Q48081326 | The relationship between high-sensitivity C-reactive protein at admission and post stroke depression: a 6-month follow-up study |
| Q35016997 | The therapeutic potential of HDAC inhibitors in the treatment of multiple sclerosis |
| Q35512854 | Underweight full-term Indian neonates show differences in umbilical cord blood leukocyte phenotype: a cross-sectional study |
Search more.